LIVINGSTON, N.J.--(BUSINESS WIRE)--Columbia Laboratories, Inc. (Nasdaq:CBRX) announced today that the full report of a meta-analysis evaluating vaginally-administered progesterone versus intramuscular (IM) progesterone injections in infertility patients is available online. CRINONE® 8% was the vaginal treatment used in five out of the seven studies analyzed. Key findings of the meta-analysis show that the clinical pregnancy rate with vaginal progesterone is comparable with IM progesterone when administered at optimal dosing, and that vaginal progesterone is associated with a significantly lower rate of miscarriage than IM progesterone. The meta-analysis was initially published as an abstract and presented at the American Society of Reproductive Medicine (ASRM) annual meeting in 2007. The study was accepted for publication in Fertility and Sterility, the official journal of ASRM.
